Biogen Inc. · BIIB · FY2025 Q2 · Calendar Q3 2025

Biogen Q2 2025: Launch Products Offset MS Decline

The quarter supports a measured growth case: launch products and pipeline milestones are offsetting multiple-sclerosis pressure, but competition, reimbursement, and execution risks remain material.

Why did BIIB rise 1.1% after beating EPS estimates in FY2025 Q2?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNASDAQHealthcare $32.49B market cap
90quality score

Earnings scorecard

Reported versus consensus
Reported EPS $5.47 Consensus $3.90
EPS surprise +40.3% Reported versus consensus
Reported revenue $2.65B Consensus $2.33B
Revenue surprise +13.6% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move +1.1% Event window
SPY move -0.4% Same window
Abnormal move +1.4% Stock minus SPY
Volume 2.7× Versus trailing sessions
Subsequent drift +3.6% Up to 20 sessions
BIIBSPY benchmark

Ask FN2 about BIIB FY2025 Q2

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

The current-quarter analysis describes 7% revenue growth, a full-year EPS guidance raise, and expanded pipeline activity, while emphasizing subcutaneous LEQEMBI and broader blood-based biomarker adoption.

Guidance delta

Management raised full-year 2025 non-GAAP diluted EPS guidance to $15.50-$16.

Key takeaways

  • Revenue growth was driven by VUMERITY, LEQEMBI, SKYCLARYS, and ZURZUVAE, offsetting multiple-sclerosis franchise pressure.
  • Management highlighted pipeline progress, including Phase III starts for felzartamab, salanersen, and lupus programs.
  • Subcutaneous LEQEMBI, blood-based biomarkers, and new product launches are central to the growth narrative.

Management priorities

  • Seek approval for subcutaneous LEQEMBI maintenance and initiation.
  • Advance felzartamab, salanersen, and lupus programs through clinical development.
  • Expand manufacturing capacity and early-stage collaborations to support pipeline growth.

Follow BIIB with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
BIIB EPS earnings history estimate and actual scatter chart 10 reported fiscal quarters and 2 future estimate-only quarters. Q4 '23 estimate $3.16 Q4 '23 actual $2.95, miss Q1 '24 estimate $3.47 Q1 '24 actual $3.67, beat Q2 '24 estimate $4.07 Q2 '24 actual $5.28, beat Q3 '24 estimate $3.77 Q3 '24 actual $4.08, beat Q2 '25 estimate $3.90 Q2 '25 actual $5.47, beat Q3 '25 estimate $3.88 Q3 '25 actual $4.81, beat Q4 '25 estimate $1.63 Q4 '25 actual $1.99, beat Q1 '26 estimate $3.05 Q1 '26 actual $3.57, beat Q2 '26 estimate $2.94 Q2 '26 actual $3.60, beat Q3 '26 estimate $1.99 Q3 '26 actual $2.62, beat Q4 '26 estimate $3.54 Q1 '27 estimate $3.69
Show less

Analyst Consensus ?

ConsensusBuy49 ratings
Bullish3367.4%
Neutral1530.6%
Bearish12.0%

Analyst 52W Price Targets

$249.59Current
$157Low
$257.73Average
$415High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Piper Sandler Overweight OverweightMaintainNov 9, 2026
HC Wainwright & Co. Buy BuyMaintainNov 2, 2026
Guggenheim Buy BuyMaintainNov 2, 2026
Wedbush Neutral NeutralMaintainOct 29, 2026
UBS Buy BuyMaintainOct 29, 2026
Show 44 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $249.59. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Mizuho SecuritiesSalim Syed$271$250.43 +8.6%Nov 20, 2026
H.C. WainwrightAndrew Fein$270$251.41 +8.2%Nov 19, 2026
Piper SandlerDavid Amsellem$305$254.94 +22.2%Nov 9, 2026
GuggenheimYatin Suneja$300$253.62 +20.2%Nov 2, 2026
Freedom BrokerIlya Zubkov$275$249.65 +10.2%Oct 29, 2026
See 155 more

Track every rating change on BIIB the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE).…

Historical context

All BIIB earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the BIIB recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:55.686058+00:00
  3. Polygon adjusted daily market bars · 2026-10-04T18:40:44.143254+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-04T18:40:44.140740+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-04. For educational purposes only; not investment advice.